Literature DB >> 7768496

Serial hemodynamic measurements in well-differentiated hepatocellular carcinomas.

S Saitoh1, K Ikeda, I Koida, A Tsubota, Y Arase, K Chayama, H Kumada.   

Abstract

We performed serial hemodynamics in 15 patients with 21 well-differentiated hepatocellular carcinomas. The total length of the observation period ranged from 129 to 678 days (median, 368). We investigated both arterial and portal blood flow at intervals of at least 4 months. Arterial blood flow was measured with carbon dioxide-enhanced ultrasonography (US), and portal blood flow was measured with computed tomographic arterial portography (CTAP). None of the tumors were hypervascular on the initial study; however, by the final study nine nodules (42.9%) had become homogeneously hypervascular, two (9.5%) had become partially hypervascular, and the others did not change. Of 10 nodules without portal blood supply on any study, 8 became hypervascular by the final study. Of 11 nodules with portal blood supply on the initial study, a follow-up study showed no change in portal flow in 6 and the loss of portal flow in 5. Four of these five became hypervascular, with a documented loss of portal flow before the increase in arterial flow. The doubling time of tumors with a homogeneous increase in arterial blood flow ranged from 89 to 333 days (median, 172), whereas the doubling time of other tumors ranged from 227 to 607 days (median, 392). Thus, growth rate and vascularity in well-differentiated hepatocellular carcinoma are closely correlated. When the well-differentiated hepatocellular carcinoma has portal blood flow and is not hypervascular, it grows slowly. On the other hand, when it loses portal blood flow and becomes hypervascular, it grows rapidly.

Entities:  

Mesh:

Year:  1995        PMID: 7768496

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

1.  Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging.

Authors:  Chen-Te Chou; Jung-Mao Chou; Ting-An Chang; Shiu-Feng Huang; Chia-Bang Chen; Yao-Li Chen; Ran-Chou Chen
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

2.  Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition.

Authors:  Satoshi Mamori; Tadashi Asakura; Kiyoshi Ohkawa; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

3.  Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma.

Authors:  K Saito; S Inoue; T Saito; S Kiso; N Ito; S Tamura; H Watanabe; H Takeda; H Misawa; H Togashi; Y Matsuzawa; S Kawata
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

4.  Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma.

Authors:  Mikio Tezuka; Keiji Hayashi; Kazunori Kubota; Sachiko Sekine; Yoichi Okada; Hiroyasu Ina; Tetsuya Irie
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.487

5.  Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis.

Authors:  Piyush Nathani; Purva Gopal; Nicole Rich; Adam Yopp; Takeshi Yokoo; Binu John; Jorge Marrero; Neehar Parikh; Amit G Singal
Journal:  Gut       Date:  2020-05-12       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.